A bell rings, fifteen years of love and waiting have the answer.
On June 24, Xi'an App-Chem Bio (Tech) Co., Ltd. was successfully listed on the NASDAQ Stock Exchange, stock code BON. APPCHEM (NASDAQ: BON) Initial Public Offering of 2.2 Million Shares Shares of common stock, priced at $5 per share, raised $11 million in IPO.APPCHEM (NASDAQ: BON) is one of the few foreign main boards in Shaanxi that has been successfully listed on the overseas main board for more than ten years. It belongs to the biomedical concept stock sector. On June 24, it opened at US$6.3 per share on the first day of trading on the Nasdaq and closed at US$7.2 per share, a 44% increase from the issue price.
Founded in 2006, the company is headquartered in the Gazelle Valley Entrepreneurship R&D Park in Xi'an High-tech Zone. It is a global supplier of natural prebiotic active ingredients and human microbiome regulation solutions in China. The company's main products are natural prebiotics, including natural oligosaccharides, natural polyphenols, and natural ambergris substitute - Ambrox. The products are sold well in Japan, South Korea, the United States, the European Union and other countries and regions, and the marketing network covers the world.
As a technology-driven high-tech enterprise, the company has applied for more than 30 patents, registered more than 70 trademarks, and drafted 5 international industry standards. At present, the company has two production bases in Weinan and Tongchuan and has ISO9001, ISO22000, Kosher, Halal, FDA and other certifications. After the third production base under construction in Yumen, Gansu Province is put into operation, the company's annual production capacity will increase by more than 200%.
A happy gathering, APPCHEM Nasdaq listing celebration was successfully held.
On July 9th, the Nasdaq listing celebration of Techcomp Biotech was successfully held at Xi'an Shangri-La Hotel. Hu Yongwei, the founder and chairman of APPCHEM (NASDAQ: BON), delivered an opening speech. Leaders and guests congratulated and delivered speeches on the company's successful listing on NASDAQ.
The celebration came to an end slowly amid the chorus of all the employees of the company...
Focus on human health and start a new journey The era of national concern for health has come. The listing of Techcomp Biotech on NASDAQ is a new starting point. In the future, the company will closely focus on the consumer demand, supply chain and production end of the entire society, efficiently supply raw materials, and innovate to empower the terminal and develop into a provider of natural health solutions targeting the human microbiome.